Trial Profile

An open-label study evaluating the efficacy and safety of budesonide in the treatment of patients with immunoglobulin A nephropathy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budesonide (Primary)
Indications IgA nephropathy; Proteinuria
Focus Therapeutic Use
Acronyms BUDIGAN

Most Recent Events

21 Jun 2023 According to an Everest Medicines Media Release, Nefecon was approved in the United States under accelerated approval based on a reduction in proteinuria.
19 Feb 2020 New trial record
14 Feb 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com